A Phase 3 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 44 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 18th largest by enrollment, is one of 8 that started in 2022, is one of 14 in phase 3, and was the 15th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 496 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 23rd largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2022, is one of 18 in phase 3, and was the 26th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the prevention of migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomization Phase: one 75 mg rimegepant (BHV3000) oral disintegration tablet every other day until Week 12
Drug: Rimegepant
Randomization Phase: one matching placebo every other day until week 12
Drug: Placebo
Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
Also known as: BHV3000
Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase
Migraine day: 1) day of electronic diary (eDiary) efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more of the following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 9 to 12\])/ (total number of efficacy data days in month \[Week 9 to 12\]).
Time frame: Baseline, Week 9 to Week 12 of the DBT phase
Percentage of Participants With at Least 50% Reduction From Baseline in the Mean Number of Moderate to Severe Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase
Percentage of participants with \>= 50% reduction, from baseline in mean number of pain intensity (moderate or severe) in each month of DBT phase are included in this outcome measure. Migraine days per month are assessed as "migraine days per 4 weeks" to correspond with the 4-week visit schedule. Migraine days per month are based on 4-week intervals and are prorated to account for missing migraine reports. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 9 to 12\])/ (total number of efficacy data days in month \[Week 9 to 12\])
Time frame: Baseline, Week 9 to Week 12 of the DBT phase
Mean Change From Baseline in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Migraine day:1) day of eDiary efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. In the model analysis, this outcome was also evaluated based on the monthly number of migraine days (and estimated the migraine days per month over the entire DBT phase). The number of migraine days per month were prorated to 28 days and derived for month (i.e.,4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month/ (total number of efficacy data days in month).
Time frame: Baseline, Week 1 to Week 12 of the DBT phase
Mean Change From Baseline in Number of Migraine Days Per Month From Week 1 to 4 of the DBT Phase
Migraine day: 1) day of eDiary efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more of the following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 1 to 4\])/ (total number of efficacy data days in month \[Week 1 to 4\]).
Time frame: Baseline, Week 1 to Week 4 of the DBT phase
Mean Number of Acute Migraine-specific Medication Days Per Month From Week 9 to 12 of the DBT Phase
An acute migraine-specific medication day was defined as day of eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or aura. Migraine days per month are assessed as "migraine days per 4 weeks" to correspond with the 4-week visit schedule. Migraine days per month are based on 4-week intervals and are prorated to account for missing migraine reports. The number of acute migraine-specific medication days per month was prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period: 28\*(total number of acute migraine-specific medication days in the month \[Week 9 to 12\])/ (total number of efficacy data days in the month \[Week 9 to 12\]).
Time frame: Week 9 to Week 12 of the DBT phase
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) v 2.1 Role Function - Restrictive Domain Score at Week 12 of the DBT Phase
MSQoL is a self-administered, 14-item instrument validated in 3 domains: role restriction, role prevention, and the emotional function. The role function-restrictive domain consists of 7 items that describe how migraine limits one's daily social and work-related activities. Participants respond to items using a 6-point scale: "none of the time," "a little bit of the time," "some of the time," "a good bit of the time," "most of the time," and "all of the time," which are assigned scores of 1 to 6, respectively. Item scores are recoded using (7 - original score). Next, raw dimension scores are computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life. The change from baseline was calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.
Time frame: Baseline, Week 12 of the DBT phase
Mean Change From Baseline in the Migraine Disability Assessment Total Score (MIDAS) at Week 12 of the DBT Phase
MIDAS is a retrospective, self-administered, 5-item questionnaire that measures headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provide the number of missed work or school days; missed household chores days; missed social or leisure activity days; and days at work or school, and separately at home, where productivity was reduced by half or more in the last 3 months (scale: 0 - 90 for each of 5 subscales). The 5 subscale scores are summed to compute the MIDAS total score (scale: 0 - 450). Lower scores indicate less headache-related disability. The change from baseline was calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.
Time frame: Baseline, Week 12 of the DBT phase
Mean Change From Baseline in the EuroQol 5 Dimensions 5-level (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Week 12 of the DBT Phase
EQ-5D-5L is a standardized measure of health status. The EQ-5D-5L consisted of EQ-5D-5L descriptive system and the EQ VAS. For EQ VAS participant rated their overall health status from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.
Time frame: Baseline, Week 12 of the DBT phase
Number of Participants With Adverse Events (AEs) By Intensity in DBT Phase
An Adverse Event (AE) was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Definition of AE in terms of intensity: Mild: Is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With AEs By Intensity in Open-Label Extension (OLE) Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Definition of AE in terms of intensity: Mild: Is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Number of Participants With Serious Adverse Events (SAEs) in DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the off spring who received rimegepant were considered an important medical event.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With SAEs in OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant were considered an important medical event.
Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Number of Participants With AEs Leading to Discontinuation of Study Drug in DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with adverse events leading to discontinuation of study drug were reported.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With AEs Leading to Discontinuation of Study Drug in OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with adverse events leading to discontinuation of study drug were reported.
Time frame: From Day 1 of OL Rimegepant dosing up at Week 12 to Week 52 (40 weeks)
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase: Hematology Parameters
The laboratory parameters were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version (v)5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Hematology parameters included: eosinophils, hemoglobin (high, low), lymphocytes (high, low), white blood cell count (WBC) (low, high), platelets, and neutrophils. hematocrit, red blood cell count, Number of participants with non-zero laboratory abnormalities of hematology parameters were reported in this outcome measure.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase: Hematology Parameters
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Hematology parameters included: eosinophils, hemoglobin (high, low), lymphocytes (high, low), WBC (low, high), platelets, and neutrophils. Number of participants with non-zero laboratory abnormalities of hematology parameters were reported in this outcome measure.
Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase: Serum Chemistry Parameters
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Serum chemistry parameters included: creatine kinase, low density lipoprotein (LDL) cholesterol, LDL cholesterol, fasting, triglycerides, triglycerides, fasting and not fasting, alanine aminotransferase increased, albumin, alkaline phosphatase, aspartate aminotransferase increased, bicarbonate, bilirubin, calcium (high, low), cholesterol, creatinine, estimated glomerular filtration rate (eGFR), glucose (high, low), lactate dehydrogenase, LDL cholesterol, potassium (high, low), sodium (high, low), and uric acid. Number of participants with non-zero laboratory abnormalities of serum chemistry parameters were reported in this outcome measure.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase: Serum Chemistry Parameters
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Serum chemistry parameters included: creatine kinase, LDL cholesterol, LDL cholesterol, triglycerides, triglycerides, alanine aminotransferase increased, albumin, alkaline phosphatase, aspartate aminotransferase increased, bicarbonate, bilirubin, calcium (high, low), cholesterol, creatinine, eGFR, glucose (high, low), lactate dehydrogenase, potassium (high, low), sodium (high, low), uric acid. Number of participants with non-zero laboratory abnormalities of serum chemistry parameters were reported in this outcome measure.
Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Number of Participants With Grade 3 to 4 Changes in DBT Phase: Urinalysis
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Urinalysis parameters included: urine glucose and urine protein.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With Grade 3 to 4 Changes in OLE Phase: Urinalysis
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Urinalysis parameters included: urine glucose and urine protein. Number of participants with non-zero laboratory abnormalities of urinalysis parameters were reported in this outcome measure.
Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Number of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3* Upper Lower Limit of Normal (ULN) Concurrent With Total Bilirubin (TBIL) >2*ULN in DBT Phase
Number of participants with ALT or AST \>3\*ULN concurrent with TBIL \>2\*ULN in DBT phase were reported in this outcome measure.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With ALT or AST> 3* ULN Concurrent With TBIL >2* ULN in OLE Phase
Number of participants with ALT or AST \>3\*ULN concurrent with TBIL \>2\*ULN in OLE phase were reported in this outcome measure.
Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Number of Participants With Hepatic-related AEs in the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With Hepatic-related AEs in the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure.
Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure. Number of participants with Hepatic-related AEs leading to study drug discontinuation were reported in this outcome measure.
Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure. Number of participants with Hepatic-related AEs leading to study drug discontinuation were reported in this outcome measure.
Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
| Milestone | Rimegepant | Placebo |
|---|---|---|
| Started | 247 | 249 |
| Completed | 233 | 238 |
| Not completed | 14 | 11 |
| Withdrew: Other | 6 | 5 |
| Withdrew: Protocol-specified withdrawal criterion met | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Adverse event | 2 | 1 |
| Milestone | Rimegepant | Placebo |
|---|---|---|
| Started | 227 | 231 |
| Completed | 204 | 215 |
| Not completed | 23 | 16 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Other | 5 | 5 |
| Withdrew: Withdrawal by subject | 12 | 7 |
| Withdrew: Pregnancy | 0 | 2 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Adverse event | 2 | 2 |
Migraine day: 1) day of electronic diary (eDiary) efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more of the following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 9 to 12\])/ (total number of efficacy data days in month \[Week 9 to 12\]).
| Days/month | Rimegepant | Placebo |
|---|---|---|
| Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase | -2.4 (-2.93 to -1.96) | -1.4 (-1.87 to -0.91) |
Percentage of participants with \>= 50% reduction, from baseline in mean number of pain intensity (moderate or severe) in each month of DBT phase are included in this outcome measure. Migraine days per month are assessed as "migraine days per 4 weeks" to correspond with the 4-week visit schedule. Migraine days per month are based on 4-week intervals and are prorated to account for missing migraine reports. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 9 to 12\])/ (total number of efficacy data days in month \[Week 9 to 12\])
| Percentage of participants | Rimegepant | Placebo |
|---|---|---|
| Percentage of Participants With at Least 50% Reduction From Baseline in the Mean Number of Moderate to Severe Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase | 41.7 (35.5 to 47.9) | 34.4 (28.5 to 40.4) |
Migraine day:1) day of eDiary efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. In the model analysis, this outcome was also evaluated based on the monthly number of migraine days (and estimated the migraine days per month over the entire DBT phase). The number of migraine days per month were prorated to 28 days and derived for month (i.e.,4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month/ (total number of efficacy data days in month).
| Days/month | Rimegepant | Placebo |
|---|---|---|
| Mean Change From Baseline in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) | -2.5 (-2.91 to -2.15) | -1.1 (-1.47 to -0.64) |
Migraine day: 1) day of eDiary efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more of the following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 1 to 4\])/ (total number of efficacy data days in month \[Week 1 to 4\]).
| Days/month | Rimegepant | Placebo |
|---|---|---|
| Mean Change From Baseline in Number of Migraine Days Per Month From Week 1 to 4 of the DBT Phase | -2.7 (-3.11 to -2.20) | -0.8 (-1.26 to -0.32) |
An acute migraine-specific medication day was defined as day of eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or aura. Migraine days per month are assessed as "migraine days per 4 weeks" to correspond with the 4-week visit schedule. Migraine days per month are based on 4-week intervals and are prorated to account for missing migraine reports. The number of acute migraine-specific medication days per month was prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period: 28\*(total number of acute migraine-specific medication days in the month \[Week 9 to 12\])/ (total number of efficacy data days in the month \[Week 9 to 12\]).
| Days/month | Rimegepant | Placebo |
|---|---|---|
| Mean Number of Acute Migraine-specific Medication Days Per Month From Week 9 to 12 of the DBT Phase | 5.0 (4.40 to 5.55) | 5.8 (5.24 to 6.40) |
MSQoL is a self-administered, 14-item instrument validated in 3 domains: role restriction, role prevention, and the emotional function. The role function-restrictive domain consists of 7 items that describe how migraine limits one's daily social and work-related activities. Participants respond to items using a 6-point scale: "none of the time," "a little bit of the time," "some of the time," "a good bit of the time," "most of the time," and "all of the time," which are assigned scores of 1 to 6, respectively. Item scores are recoded using (7 - original score). Next, raw dimension scores are computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life. The change from baseline was calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.
| Score on a scale | Rimegepant | Placebo |
|---|---|---|
| Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) v 2.1 Role Function - Restrictive Domain Score at Week 12 of the DBT Phase | 7.8 (6.20 to 9.44) | 3.7 (2.05 to 5.36) |
MIDAS is a retrospective, self-administered, 5-item questionnaire that measures headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provide the number of missed work or school days; missed household chores days; missed social or leisure activity days; and days at work or school, and separately at home, where productivity was reduced by half or more in the last 3 months (scale: 0 - 90 for each of 5 subscales). The 5 subscale scores are summed to compute the MIDAS total score (scale: 0 - 450). Lower scores indicate less headache-related disability. The change from baseline was calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.
| Score on a scale | Rimegepant | Placebo |
|---|---|---|
| Mean Change From Baseline in the Migraine Disability Assessment Total Score (MIDAS) at Week 12 of the DBT Phase | -4.0 (-5.57 to -2.42) | -1.6 (-3.88 to 0.70) |
EQ-5D-5L is a standardized measure of health status. The EQ-5D-5L consisted of EQ-5D-5L descriptive system and the EQ VAS. For EQ VAS participant rated their overall health status from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.
| Score on a scale | Rimegepant | Placebo |
|---|---|---|
| Mean Change From Baseline in the EuroQol 5 Dimensions 5-level (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Week 12 of the DBT Phase | 3.5 (1.60 to 5.37) | 0.8 (-1.40 to 3.02) |
An Adverse Event (AE) was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Definition of AE in terms of intensity: Mild: Is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Any AE | 135 | 102 |
| Mild AE | 110 | 96 |
| Moderate AE | 24 | 6 |
| Severe AE | 1 | 0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Definition of AE in terms of intensity: Mild: Is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| Any AE | 162 | 175 |
| Mild AE | 127 | 141 |
| Moderate AE | 33 | 33 |
| Severe AE | 2 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the off spring who received rimegepant were considered an important medical event.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) in DBT Phase | 2 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant were considered an important medical event.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| Number of Participants With SAEs in OLE Phase | 4 | 0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with adverse events leading to discontinuation of study drug were reported.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Number of Participants With AEs Leading to Discontinuation of Study Drug in DBT Phase | 4 | 2 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with adverse events leading to discontinuation of study drug were reported.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| Number of Participants With AEs Leading to Discontinuation of Study Drug in OLE Phase | 2 | 4 |
The laboratory parameters were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version (v)5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Hematology parameters included: eosinophils, hemoglobin (high, low), lymphocytes (high, low), white blood cell count (WBC) (low, high), platelets, and neutrophils. hematocrit, red blood cell count, Number of participants with non-zero laboratory abnormalities of hematology parameters were reported in this outcome measure.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Hemoglobin, low | 2 | 0 |
| Neutrophils | 4 | 0 |
| Platelets | 1 | 0 |
| White blood cell count, low | 1 | 0 |
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Hematology parameters included: eosinophils, hemoglobin (high, low), lymphocytes (high, low), WBC (low, high), platelets, and neutrophils. Number of participants with non-zero laboratory abnormalities of hematology parameters were reported in this outcome measure.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| Hemoglobin, low | 2 | 1 |
| Lymphocytes, low | 1 | 1 |
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Serum chemistry parameters included: creatine kinase, low density lipoprotein (LDL) cholesterol, LDL cholesterol, fasting, triglycerides, triglycerides, fasting and not fasting, alanine aminotransferase increased, albumin, alkaline phosphatase, aspartate aminotransferase increased, bicarbonate, bilirubin, calcium (high, low), cholesterol, creatinine, estimated glomerular filtration rate (eGFR), glucose (high, low), lactate dehydrogenase, LDL cholesterol, potassium (high, low), sodium (high, low), and uric acid. Number of participants with non-zero laboratory abnormalities of serum chemistry parameters were reported in this outcome measure.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Creatine kinase | 4 | 0 |
| LDL cholesterol | 0 | 4 |
| Triglycerides | 1 | 0 |
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Serum chemistry parameters included: creatine kinase, LDL cholesterol, LDL cholesterol, triglycerides, triglycerides, alanine aminotransferase increased, albumin, alkaline phosphatase, aspartate aminotransferase increased, bicarbonate, bilirubin, calcium (high, low), cholesterol, creatinine, eGFR, glucose (high, low), lactate dehydrogenase, potassium (high, low), sodium (high, low), uric acid. Number of participants with non-zero laboratory abnormalities of serum chemistry parameters were reported in this outcome measure.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| LDL cholesterol | 7 | 7 |
| Triglycerides | 1 | 1 |
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Urinalysis parameters included: urine glucose and urine protein.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Number of Participants With Grade 3 to 4 Changes in DBT Phase: Urinalysis | 0 | 0 |
The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Urinalysis parameters included: urine glucose and urine protein. Number of participants with non-zero laboratory abnormalities of urinalysis parameters were reported in this outcome measure.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| Number of Participants With Grade 3 to 4 Changes in OLE Phase: Urinalysis | 3 | 1 |
Number of participants with ALT or AST \>3\*ULN concurrent with TBIL \>2\*ULN in DBT phase were reported in this outcome measure.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Number of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3* Upper Lower Limit of Normal (ULN) Concurrent With Total Bilirubin (TBIL) >2*ULN in DBT Phase | 0 | 0 |
Number of participants with ALT or AST \>3\*ULN concurrent with TBIL \>2\*ULN in OLE phase were reported in this outcome measure.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| Number of Participants With ALT or AST> 3* ULN Concurrent With TBIL >2* ULN in OLE Phase | 0 | 0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Number of Participants With Hepatic-related AEs in the DBT Phase | 3 | 4 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| Number of Participants With Hepatic-related AEs in the OLE Phase | 8 | 7 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure. Number of participants with Hepatic-related AEs leading to study drug discontinuation were reported in this outcome measure.
| Participants | Rimegepant | Placebo |
|---|---|---|
| Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the DBT Phase | 0 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure. Number of participants with Hepatic-related AEs leading to study drug discontinuation were reported in this outcome measure.
| Participants | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|
| Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the OLE Phase | 2 | 1 |
Collected over DBT phase: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks); OLE phase: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBT: Rimegepant | 0/247 (0%) | 2/247 (0.8%) | 85/247 (34.4%) |
| DBT: Placebo | 0/249 (0%) | 1/249 (0.4%) | 73/249 (29.3%) |
| DBT Rimegepant/OLE Rimegepant | 0/227 (0%) | 4/227 (1.8%) | 148/227 (65.2%) |
| DBT Placebo/OLE Rimegepant | 0/231 (0%) | 0/231 (0%) | 150/231 (64.9%) |
| Event | DBT: Rimegepant | DBT: Placebo | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/247 | 0/249 | 1/227 | 0/231 |
| Hepatic function abnormalHepatobiliary disorders | 0/247 | 0/249 | 1/227 | 0/231 |
| Nodal osteoarthritisMusculoskeletal and connective tissue disorders | 0/247 | 0/249 | 1/227 | 0/231 |
| Coronavirus infectionInfections and infestations | 0/247 | 0/249 | 1/227 | 0/231 |
| Pancreatitis acuteGastrointestinal disorders | 1/247 | 0/249 | 0/227 | 0/231 |
| COVID-19Infections and infestations | 1/247 | 0/249 | 0/227 | 0/231 |
| AppendicitisInfections and infestations | 0/247 | 1/249 | 0/227 | 0/231 |
| Event | DBT: Rimegepant | DBT: Placebo | DBT Rimegepant/OLE Rimegepant | DBT Placebo/OLE Rimegepant |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 21/247 | 25/249 | 51/227 | 64/231 |
| COVID-19Infections and infestations | 6/247 | 7/249 | 32/227 | 28/231 |
| Back painMusculoskeletal and connective tissue disorders | 3/247 | 6/249 | 15/227 | 9/231 |
| InfluenzaInfections and infestations | 5/247 | 5/249 | 11/227 | 14/231 |
| Coronavirus infectionInfections and infestations | 8/247 | 4/249 | 12/227 | 10/231 |
| PyrexiaGeneral disorders | 6/247 | 5/249 | 7/227 | 12/231 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 9/247 | 8/249 | 11/227 | 10/231 |
| ConstipationGastrointestinal disorders | 7/247 | 1/249 | 8/227 | 8/231 |
| Dental cariesGastrointestinal disorders | 1/247 | 3/249 | 8/227 | 4/231 |
| ToothacheGastrointestinal disorders | 3/247 | 2/249 | 8/227 | 5/231 |
| Age, Continuous(Years) | Rimegepant | Placebo | Total |
|---|---|---|---|
| Mean | 44.9 ± 9.52 | 43.1 ± 10.68 | 44.0 ± 10.15 |
| Sex: Female, Male(Participants) | Rimegepant | Placebo | Total |
|---|---|---|---|
| Female | 225 | 221 | 446 |
| Male | 22 | 28 | 50 |
| Race and Ethnicity Not Collected(Participants) | Rimegepant | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2022 to primary completion in Jan 2024, 17 months.
Results were first posted in Jul 2025, 1 year 5 months after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 17 months is close to that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant